Difference between revisions of "Team:Shanghai Metro/Proof Of Concept"

(Prototype team page)
 
Line 1: Line 1:
{{IGEM_TopBar}}
+
<html lang="en">
{{Shanghai_Metro}}
+
<html>
+
  
 +
<head>
 +
    <meta charset="UTF-8">
 +
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
 +
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
 +
    <title>Shanghai_Metro</title>
 +
    <link rel="stylesheet"
 +
        href="https://2021.igem.org/wiki/index.php?title=Template:Shanghai_Metro/Main_CSS&action=raw&ctype=text/css" />
  
<div class="column full_size judges-will-not-evaluate">
+
</head>
<h3>★  ALERT! </h3>
+
<p>This page is used by the judges to evaluate your team for the <a href="https://2021.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2021.igem.org/Judging/Awards"> award listed below</a>. </p>
+
<p> Delete this box in order to be evaluated for this medal criterion and/or award. See more information at <a href="https://2021.igem.org/Judging/Pages_for_Awards"> Instructions for Pages for awards</a>.</p>
+
</div>
+
 
+
 
+
<div class="clear"></div>
+
 
+
 
+
<div class="column full_size">
+
<h1>Proof of Concept</h1>
+
<h3>Gold Medal Criterion #4</h3>
+
<p>Expand upon your Silver medal work for Proposed Implementation and develop a proof of concept for your project.
+
 
+
<br><br>
+
Please see the <a href="https://2021.igem.org/Judging/Medals">2021 Medals Page</a> for more information. </p>
+
</div>
+
  
 +
<body>
 +
    <nav class="head-nav clearfix">
 +
        <div class="top-block"></div>
 +
        <div class="top-nav-bar">
 +
            <ul class="clearfix">
 +
                <span class="small-logo"></span>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro">Home</a>
 +
                </li>
 +
                <li class="active">
 +
                    <a href="">Project</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Description"
 +
                                    class="sub-nav-74">Description</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Experiments"
 +
                                    class="sub-nav-74">Experiments</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Results"
 +
                                    class="sub-nav-74">Results</a></li>
 +
                            <li class="current-sub-nav"><a href="#" class="sub-nav-52">Proof Of Concept</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Notebook"
 +
                                    class="sub-nav-52">Notebook</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Safety">Safety</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li>
 +
                    <a href="">Parts</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Collection" class="sub-nav-74">Parts
 +
                                    Collection</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Engineering"
 +
                                    class="sub-nav-74">Engineering</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li>
 +
                    <a href="">Human Practices</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Human_Practices"
 +
                                    class="sub-nav-74">Integrated Human Practice</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Communication"
 +
                                    class="sub-nav-74">Communication</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Fundraising"
 +
                                    class="sub-nav-74">Fundraising</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro/Implementation">Implementation</a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro/Entrepreneurship">Entrepreneurship</a>
 +
                </li>
 +
                <li>
 +
                    <a href="https://2021.igem.org/Team:Shanghai_Metro/Model">Model</a>
 +
                </li>
 +
                <li>
 +
                    <a href="">Team</a>
 +
                    <div class="sub-nav">
 +
                        <ul>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Members" class="sub-nav-74">Team
 +
                                    Members</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Attributions"
 +
                                    class="sub-nav-74">Attributions</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Collaborations"
 +
                                    class="sub-nav-74">Collaborations</a></li>
 +
                            <li><a href="https://2021.igem.org/Team:Shanghai_Metro/Partnership"
 +
                                    class="sub-nav-74">Partnership</a></li>
 +
                        </ul>
 +
                    </div>
 +
                </li>
 +
            </ul>
 +
        </div>
 +
    </nav>
 +
    <div class="sub-content">
 +
        <div class="sub-title">PROOF OF CONCEPT</div>
 +
        <div class="article-title">1. Theory and analysis</div>
 +
        <div class="article-content">1) Rationale</div>
 +
        <div class="article-content">The topic was inspired by the Type VI secretion system (T6SS) of Pseudomonas
 +
            putida. T6SS kill eukaryotic predators or its competitors by injecting anti-bacterial effectors, the toxic
 +
            substances, into eukaryotic or prokaryotic cells. Pseudomonas putida itself will not be killed by the
 +
            anti-bacterial effectors because it secrets immunity proteins specific to each of their antibacterial
 +
            effector proteins to protect itself. <sup>[1]</sup> Based on this theory, we want to transfer tke2/4, the
 +
            anti-bacterial effectors, and ike2/4, the immunity proteins to the plasmid of protected bacterial species.
 +
            Protect the bacterial species by controlling the immunity proteins.</div>
 +
        <div class="article-content">2) Theory explanation</div>
 +
        <div class="article-content">The DNA sequences of immunity protein ike2/4 and the anti-bacterial effector tke2/4
 +
            in Pseudomonas putida are extracted, and they are connected to Pus232 backbone by T4 DNA
 +
            ligase.<sup>[2]</sup> Then,
 +
            Pus232-ike2/4 is linearized by single enzyme digestion. Later on, the tke2/4 is connected to Pus232-ike2/4
 +
            through homologous recombination enzyme.<sup>[3]</sup> After employing a complicated process,
 +
            Pus232-ike2/4-tke2/4
 +
            plasmid is finally obtained. Tetracycline is then added to LB medium (solid) to induce the expression of
 +
            ike2/4, so that the bacterial species can survive eventually.</div>
 +
        <div class="article-title">2. Product performance</div>
 +
        <div class="article-content">In order to make sure that our protection plasmid works, we tested to find the
 +
            optimal amount of our inducer tetracycline and the growth speed of ike2/tke2 or ike4/tke4 types by using
 +
            OD<sub>600</sub> testing.</div>
 +
        <div class="article-content">Tetracycline amount determination:</div>
 +
        <div class="article-content" style="padding-left: 30px; box-sizing: border-box;">● In order to eventually
 +
            determine the specific
 +
            tetracycline amount and make sure our protection plasmid works, we set up a control group with only Pus232
 +
            strains and a test group with Pus232-tke4-ike4 strains. We each added either none, 25µg/L, 50µg/L, 75µg/L,
 +
            100µg/L, 200µg/L, 300µg/L, 400µg/L, 500µg/L, 600µg/L, 700µg/L, 800µg/L, 900µg/L, 1000µg/L, or 2000µg/L of
 +
            tetracycline to the control group and test group. The test group results showed that the growth greatly
 +
            increased and possibly at its best with adding tetracycline concentrations at the range of
 +
            300-500µg/L(Fig.1), while the effect to Pus232 strain alone is less obvious(Fig.2). The control group
 +
            ensured that tetracycline alone harms growth of ordinary strains by showing a decreasing pattern of biomass
 +
            concentration adding tetracycline concentrations over 500µg/L(Fig.2).</div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/f/fb/T--Shanghai_Metro--PROOF_OF_CONCEPT01.jpg" alt="" />
 +
            <span>Figure 1. Growth testing of test group Pus232-ike4-tke4 strains under different concentrations of
 +
                tetracycline.</span>
 +
        </div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/0/05/T--Shanghai_Metro--PROOF_OF_CONCEPT02.jpg" alt="" />
 +
            <span>Figure 2. Growth testing of control group Pus232 strains under different concentrations of
 +
                tetracycline.</span>
 +
        </div>
 +
        <div class="article-title">3. Protocol for users</div>
 +
        <div class="img-wrap no-margin">
 +
            <img src="https://static.igem.org/mediawiki/2021/4/43/T--Shanghai_Metro--PROOF_OF_CONCEPT03.jpg" alt="" />
 +
            <span>Figure 3. Workflow of the product</span>
 +
        </div>
 +
        <div class="article-content">When the patented strain holder receives our product, the protection plasmid can be
 +
            used for transformation directly into their patented strain, then select the positive colonies on the LB
 +
            plate with kanamycin. Pick several mono-colonies from the plate to culture as brand-new patented strains.
 +
            Tetracycline at the range of 300-500µg/L is required in the course of fermentation. If someone steals the
 +
            brand-new patented strains, they could not culture the strains or do fermentation because they do not know
 +
            the existence or a feasible concentration of tetracycline. Therefore, patented strain holder can protect
 +
            their patent(Fig.3).</div>
 +
        <div class="article-title">Bibliography</div>
 +
        <div class="article-content">1. Hernandez, Ruth E., et al. “Type Vi Secretion System Effector Proteins:
 +
            Effective Weapons for Bacterial Competitiveness.” Cellular Microbiology, vol. 22, no. 9, 2020,
 +
            doi:10.1111/cmi.13241. </div>
 +
        <div class="article-content">2. Rossi, R. “Functional Characterization of the T4 DNA Ligase: A New Insight into
 +
            the Mechanism of Action.” Nucleic Acids Research, vol. 25, no. 11, 1997, pp. 2106–2113.,
 +
            doi:10.1093/nar/25.11.2106.</div>
 +
        <div class="article-content">3. “Homologous Recombination in Procaryotes.” Microbiological Reviews, vol. 52, no.
 +
            2, 1988, pp. 304–304., doi:10.1128/mr.52.2.304-304.1988.</div>
 +
    </div>
 +
    <footer class="footer">
 +
        <section class="footer-wrap">
 +
            <p class="contact-tips">Contact Info.</p>
 +
            <hr class="line" />
 +
            <p class="margin-bottom-8">Email: <i style="color:#0030e4;">binghan423@163.com; runshigu@126.com</i></p>
 +
            <p>Wechat Official Account: IGEM VIPatent</p>
 +
        </section>
 +
    </footer>
 +
</body>
 +
<script>
 +
    let liTags = document.querySelectorAll(".top-nav-bar > ul > li");
 +
    let len = liTags.length;
 +
    for (let i = 0; i < len; i++) {
 +
        liTags[i].onclick = function (e) {
 +
            //先移除所有的点击样式
 +
            for (let j = 0; j < len; j++) {
 +
                liTags[j].classList.remove("active");
 +
            }
 +
            //再添加点击样式
 +
            let li = e.currentTarget;
 +
            li.classList.add("active");
 +
        }
 +
    }
 +
</script>
  
 
</html>
 
</html>

Revision as of 09:32, 9 October 2021

Shanghai_Metro

PROOF OF CONCEPT
1. Theory and analysis
1) Rationale
The topic was inspired by the Type VI secretion system (T6SS) of Pseudomonas putida. T6SS kill eukaryotic predators or its competitors by injecting anti-bacterial effectors, the toxic substances, into eukaryotic or prokaryotic cells. Pseudomonas putida itself will not be killed by the anti-bacterial effectors because it secrets immunity proteins specific to each of their antibacterial effector proteins to protect itself. [1] Based on this theory, we want to transfer tke2/4, the anti-bacterial effectors, and ike2/4, the immunity proteins to the plasmid of protected bacterial species. Protect the bacterial species by controlling the immunity proteins.
2) Theory explanation
The DNA sequences of immunity protein ike2/4 and the anti-bacterial effector tke2/4 in Pseudomonas putida are extracted, and they are connected to Pus232 backbone by T4 DNA ligase.[2] Then, Pus232-ike2/4 is linearized by single enzyme digestion. Later on, the tke2/4 is connected to Pus232-ike2/4 through homologous recombination enzyme.[3] After employing a complicated process, Pus232-ike2/4-tke2/4 plasmid is finally obtained. Tetracycline is then added to LB medium (solid) to induce the expression of ike2/4, so that the bacterial species can survive eventually.
2. Product performance
In order to make sure that our protection plasmid works, we tested to find the optimal amount of our inducer tetracycline and the growth speed of ike2/tke2 or ike4/tke4 types by using OD600 testing.
Tetracycline amount determination:
● In order to eventually determine the specific tetracycline amount and make sure our protection plasmid works, we set up a control group with only Pus232 strains and a test group with Pus232-tke4-ike4 strains. We each added either none, 25µg/L, 50µg/L, 75µg/L, 100µg/L, 200µg/L, 300µg/L, 400µg/L, 500µg/L, 600µg/L, 700µg/L, 800µg/L, 900µg/L, 1000µg/L, or 2000µg/L of tetracycline to the control group and test group. The test group results showed that the growth greatly increased and possibly at its best with adding tetracycline concentrations at the range of 300-500µg/L(Fig.1), while the effect to Pus232 strain alone is less obvious(Fig.2). The control group ensured that tetracycline alone harms growth of ordinary strains by showing a decreasing pattern of biomass concentration adding tetracycline concentrations over 500µg/L(Fig.2).
Figure 1. Growth testing of test group Pus232-ike4-tke4 strains under different concentrations of tetracycline.
Figure 2. Growth testing of control group Pus232 strains under different concentrations of tetracycline.
3. Protocol for users
Figure 3. Workflow of the product
When the patented strain holder receives our product, the protection plasmid can be used for transformation directly into their patented strain, then select the positive colonies on the LB plate with kanamycin. Pick several mono-colonies from the plate to culture as brand-new patented strains. Tetracycline at the range of 300-500µg/L is required in the course of fermentation. If someone steals the brand-new patented strains, they could not culture the strains or do fermentation because they do not know the existence or a feasible concentration of tetracycline. Therefore, patented strain holder can protect their patent(Fig.3).
Bibliography
1. Hernandez, Ruth E., et al. “Type Vi Secretion System Effector Proteins: Effective Weapons for Bacterial Competitiveness.” Cellular Microbiology, vol. 22, no. 9, 2020, doi:10.1111/cmi.13241.
2. Rossi, R. “Functional Characterization of the T4 DNA Ligase: A New Insight into the Mechanism of Action.” Nucleic Acids Research, vol. 25, no. 11, 1997, pp. 2106–2113., doi:10.1093/nar/25.11.2106.
3. “Homologous Recombination in Procaryotes.” Microbiological Reviews, vol. 52, no. 2, 1988, pp. 304–304., doi:10.1128/mr.52.2.304-304.1988.